Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus VCD in treatment-naive multiple myeloma
ACTRN12612000779875Phase 2Withdrawn
- Sponsor
- North Shore Haematology Clinical Trial Unit
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat in multiple myeloma (MM) (4 arms), sponsored by North Shore Haematology Clinical Trial Unit. Primary endpoint: Toxicity of escalating doses of panobinostat combined with VCD. Planned start Feb 2014; status: withdrawn.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12612000779875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000779875.